ORPHA Stock Overview
Orphazyme A/S does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Orphazyme A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.1.00 |
| 52 Week High | kr.5.37 |
| 52 Week Low | kr.0.68 |
| Beta | 0.23 |
| 1 Month Change | -12.54% |
| 3 Month Change | -37.33% |
| 1 Year Change | -22.47% |
| 3 Year Change | -98.56% |
| 5 Year Change | -98.44% |
| Change since IPO | -98.75% |
Recent News & Updates
Shareholder Returns
| ORPHA | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | 0.4% | -2.9% | -0.9% |
| 1Y | -22.5% | -2.1% | 28.2% |
Return vs Industry: ORPHA underperformed the Danish Biotechs industry which returned 3.1% over the past year.
Return vs Market: ORPHA underperformed the Danish Market which returned 32.7% over the past year.
Price Volatility
| ORPHA volatility | |
|---|---|
| ORPHA Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in DK Market | 9.4% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: ORPHA is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ORPHA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Anders Vadsholt | https://www.orphazyme.com |
Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Orphazyme A/S Fundamentals Summary
| ORPHA fundamental statistics | |
|---|---|
| Market Cap | kr.35.45m |
| Earnings (TTM) | -kr.26.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs ORPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORPHA income statement (TTM) | |
|---|---|
| Revenue | kr.0 |
| Cost of Revenue | kr.0 |
| Gross Profit | kr.0 |
| Other Expenses | kr.26.65m |
| Earnings | -kr.26.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ORPHA perform over the long term?
See historical performance and comparison